Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

256.51
+1.030.40%
Volume:973.33K
Turnover:248.52M
Market Cap:453.35B
PE:72.47
High:256.75
Open:254.17
Low:252.33
Close:255.48
52wk High:267.47
52wk Low:190.75
Shares:1.77B
Float Shares:1.76B
Volume Ratio:0.49
T/O Rate:0.06%
Dividend:6.83
Dividend Rate:2.66%
EPS(TTM):3.54
EPS(LYR):2.36
ROE:6225.00%
ROA:10.51%
PB:-76.39
PE(LYR):108.69

Loading ...

Abbvie Shares Down 2.2% After Co Trims 2026 Profit Forecast

THOMSON REUTERS
·
Jul 31

Abbvie Exec Says NOW Expect Total Annual Net Revenue of Approximately $67.6 Billion, Increase of $300 Million Versus Previous Forecast - Conf Call

THOMSON REUTERS
·
Jul 31

Abbvie Exec Says in Third Quarter it Expects Adjusted Profit Per Share Between $3.84 and $3.88 - Conf Call

THOMSON REUTERS
·
Jul 31

AbbVie Bought Apogee to Strengthen Its Portfolio. Now It's Cutting Earnings Guidance.

Dow Jones
·
Jul 31

AbbVie Lowers Outlook to Account for Acquisition, as 2Q Profit Jumps

Dow Jones
·
Jul 31

AbbVie Q2 Adjusted Earnings, Revenue Rise

MT Newswires Live
·
Jul 31

AbbVie Falls After Trimming 2026 Profit Forecast

Reuters
·
Jul 31

AbbVie Beats Q2 Revenue, Adjusted EPS Estimates but Cuts FY Adj EPS Guidance

Reuters
·
Jul 31

Movement Alert|AbbVie Falls 4.29% in Pre-Market Trading, Q2 Earnings Beat Expectations but Acquisition Dilution Weighs on Full-Year Guidance

Market Focus
·
Jul 31

AbbVie Q2 2026 earnings: Immunology and neuroscience drive 10.2% revenue growth

TradingKey
·
Jul 31

Abbvie Shares Down 3.6% Premarket After Co Cuts 2026 Profit Forecast on Apogee Buy

THOMSON REUTERS
·
Jul 31

GUIDANCE: (ABBV) AbbVie Expects 2026 Adjusted EPS Range $13.87 - $14.07, vs. FactSet Est of $14.06

MT Newswires Live
·
Jul 31

AbbVie Q2 Adj. EPS $3.65 Beats $3.60 Estimate, Sales $16.990B Beat $16.765B Estimate

Benzinga Earnings
·
Jul 31

AbbVie Trims 2026 Profit Forecast on Apogee Buy, Beats Second-quarter Estimates

Reuters
·
Jul 31

AbbVie Q2 GAAP EPS Climbs 290.4% to $2.03; Net Revenues Rise 10.2% to $16.99 Billion vs Q2 FY25

Reuters
·
Jul 31

Abbvie : FY 2026 Adj EPS Guidance Includes $0.14 /Share Dilutive Impact Related to Acquisition of Apogee Therapeutics

THOMSON REUTERS
·
Jul 31

Abbvie Inc Q2 Global Skyrizi Revenue USD 5,505 Million

THOMSON REUTERS
·
Jul 31

Abbvie Inc Q2 Global Humira Revenue USD 756 Million

THOMSON REUTERS
·
Jul 31

Abbvie : Q2 Results Include an Unfavorable Impact of $0.17/Share Related to Acquired Ipr&D and Milestones Expense

THOMSON REUTERS
·
Jul 31

Abbvie Inc Outlook FY Adjusted EPS USD 0.14 VS. Ibes Estimate USD 14.1

THOMSON REUTERS
·
Jul 31